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background: Glycoprotein (Gp) IIbIIIa receptor inhibitors are known to reduce mortality, target vessel revascularization but not re-infarction in ST 
elevation myocardial infarction (STEMI) patients. We investigated the impact of Gp IIbIIIa receptor inhibitors on the post procedure TIMI flow and 1 
month major clinical outcomes in diabetic STEMI patients undergoing primary percutaneous coronary intervention (PCI).
methods: Total of 1562 diabetic STEMI patients undergoing primary PCI with or without periprocedural Gp IIbIIIa receptor inhibitor coverage were 
identified from Korean AMI registry (KAMIR). Among 1562 patients, 1107 patients didn’t receive periprocedural GP IIbIIIa receptor inhibitors and 365 
patients received.
results: Baseline characteristics were balanced between the two groups except for gender and the incidence of ischemic heart disease. There 
was no significant impact of GPIIbIIIa receptor inhibitor on the post procedure TIMI flow and 1month major clinical outcomes (Table). Among no Gp 
IIbIIIa receptor inhibitor usage patients, 80.3% achieved TIMI III flow and 81.6% in the Gp IIbIIIa receptor inhibitor usage.
Conclusions: Although the Gp IIbIIIa receptor inhibitor is known to reduce mortality and target vessel revascularization in STEMI patients, there 
was no statistically significant impact on the post procedural TIMI flow and 1month major clinical outcomes in diabetic STEMI patients undergoing 
primary PCI.
 
